Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Braidwell LP

Braidwell LP reduced its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 28.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 707,240 shares of the company's stock after selling 274,969 shares during the quarter. Braidwell LP owned approximately 1.75% of Keros Therapeutics worth $41,069,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. KBC Group NV grew its holdings in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after buying an additional 432 shares during the last quarter. Arizona State Retirement System increased its position in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company's stock worth $369,000 after buying an additional 1,130 shares in the last quarter. American International Group Inc. raised its holdings in shares of Keros Therapeutics by 13.1% in the first quarter. American International Group Inc. now owns 12,653 shares of the company's stock worth $838,000 after acquiring an additional 1,465 shares during the last quarter. Finally, Algert Global LLC raised its holdings in shares of Keros Therapeutics by 10.6% in the second quarter. Algert Global LLC now owns 15,700 shares of the company's stock worth $717,000 after acquiring an additional 1,505 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KROS. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a "buy" rating for the company. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a "buy" rating and a $96.00 target price for the company. Finally, Bank of America reduced their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating on the stock in a research note on Thursday, September 12th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $88.89.

Keros Therapeutics Stock Down 1.4 %

Shares of NASDAQ KROS traded down $0.81 during trading on Friday, hitting $57.74. 125,835 shares of the company traded hands, compared to its average volume of 373,627. The firm has a market capitalization of $2.34 billion, a P/E ratio of -11.08 and a beta of 1.23. The company has a 50-day moving average price of $59.49 and a 200-day moving average price of $52.29. Keros Therapeutics, Inc. has a 1 year low of $27.31 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company's revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.33) EPS. Research analysts predict that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.